Abstract
Royal jelly is a nutritious substance produced by the hypopharyngeal and mandibular glands of honeybees. Royal jelly possesses many attractive and beneficial properties which make it an ideal component in medical and pharmaceutical products. The antibacterial, antioxidant, and anti-inflammatory activities of royal jelly from honeybees (Apis mellifera) were determined in this study. Moreover, the total phenolic and flavonoid contents of the royal jelly were also evaluated. The effects of royal jelly on growth inhibition against skin pathogenic bacteria, including Cutibacterium acnes, methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, and Corynebacterium spp., were investigated by the agar well diffusion method. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were further determined by the broth dilution method. The results indicated that royal jelly showed antibacterial activity by inhibiting the growth of Gram-positive pathogenic bacteria, while the effectiveness decreased against Gram-negative bacteria. Interestingly, royal jelly from Lamphun (RJ-LP1), and Chiang Mai (RJ-CM1), presented high inhibitory efficacy against C. acnes, MRSA, and S. aureus within 4 h by a time killing assay. Furthermore, the anti-inflammatory properties of royal jelly were tested using RAW264.7 macrophage cells, and results revealed that RJ-LP1 and RJ-CM1 could reduce nitric oxide (NO) production and suppress iNOS gene expression. After testing the antioxidant activity, RJ-CM1 and RJ-CM2 of royal jelly from Chiang Mai had the highest level. Additionally, RJ-CM1 also showed the highest total phenolic and flavonoid content. These findings have brought forward new knowledge of the antibacterial, antioxidant, and anti-inflammatory properties of royal jelly, which will improve clinical and pharmaceutical uses of royal jelly as an alternative therapy for bacterial infections, and also as a dietary supplement product.